CTHRPHA@EC2605A

Hengrui's Partner Kailera Publishes Phase 2 Clinical Trial Data for GLP-1/GIP Receptor Dual Agonist Peptide HRS9531

Huahai Medicine Subsidiary Product Granted Breakthrough Therapy Designation

HRS-4642 Injection Developed by Hengrui Medicine Included in Breakthrough Therapy List

Hengrui Medicine's HR091506 Tablet Marketing Authorization Application Accepted by National Medical Products Administration

Hengrui Medicine's Subsidiary's SHR-1894 Receives Clinical Trial Approval

Hengrui Medicine Repurchased 165,000 A-shares for 9.317 Million Yuan

Hengrui Medicine's Injection Carfilzumab Combined with Apatinib for First-line Treatment Receives FDA Acceptance

Huareyiyao repurchased 343,100 shares on SSE

Hengrui Medicine's Subsidiary's Application for Marketing Authorization of Phosphorolapitan Palonosetron Injection Accepted by NMPA

HRS-7535 Tablet Clinical Trial Approved for Hengrui Medicine's Subsidiary

Hengrui Medicine's Subsidiary Receives Approval to Initiate Phase III Clinical Trials for GLP-1 Receptor Agonist HRS-7535

Hengrui Medicine's Progress in Repurchasing A-shares

HRS-5346 tablet of Hengrui Medicine's subsidiary included in breakthrough therapy list

Morgan Stanley Raises Target Price for Hengrui Medicine to 92 Yuan

Hengrui Medicine Receives Approval for SHR-1049 Injection Clinical Trials

Hengrui Medicine Subsidiary Receives Approval for SHR-7787 Injection Clinical Trials

Citi Increases Short Position in Hengrui Medicine

Hengrui Medicine Receives Clinical Trial Approval Notice from NMPA

Hengrui Medicine's Subsidiary Obtains Approval for Hypertension Drug Clinical Trials

Hengrui Medicine's Subsidiary's SHR-1826 Inclusion in Breakthrough Therapy List

ELIFE HLDGS

CHERISH SUN

MOBI DEV

ADD NEW ENERGY

DAISHOMICROLINE

DT CAPITAL

NANFANG COMM

JIADING INTL GP

KINGWELL GROUP

PUTIAN COMM

516820

513060

600276

520690

01276

Nomura expects Hengrui Pharma's net profit to grow by 32% to CNY 2.3 billion in 2025, with revenue increasing by 7% year-on-year to CNY 8.3 billion, which is below market expectations. Revenue is expected to grow by 18% to CNY 37.2 billion in 2026, with net profit increasing by 30% to CNY 11.2 billion. The target price has been lowered from HKD 94.54 to HKD 87.49, maintaining a "Buy" rating

AASTOCKS

Ping An CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng Health Care ETF(QDII)

Hengrui Pharma

Bosera Hang Seng SCHK Innovative Drug Select ETF

HENGRUI PHARMA

Nomura expects Hengrui Pharma's net profit to grow by 30% this year, lowering the target price to 87.49 yuan and continuing to recommend "buy."

Jiangsu Hengrui Medicine Gets Breakthrough Therapy Designation for Cancer Drug

marketscreener

Jiangsu Hengrui Medicine Gets Breakthrough Therapy Designation for Cancer Drug

Hengrui Pharma announced that its HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center, with the intended indication being the first-line treatment for advanced or metastatic pancreatic cancer carrying the KRAS G12D mutation in combination with gemcitabine and paclitaxel

Hengrui Pharma's HRS-4642 injection has been included in the list of breakthrough therapy designations

Hengrui Pharmaceuticals' Gout Drug Application Accepted by Regulators

Hengrui Pharmaceuticals' Gout Drug Application Accepted by Regulators

Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced a delay in the re-election of its board of directors, which was originally set to occur before the term expiration on February 1, 2026. The current board members' terms will be extended to ensure stability and continuity in governance. The company assures that this delay will not affect normal operations and is working to expedite the re-election process. The latest analyst rating for the stock (HK:1276) is a Buy with a target price of HK$96.90.

Tip Ranks

Jiangsu Hengrui Pharma Delays Board Re-election, Extends Current Directors’ Terms

513120

06618

09618

02618

Jingdong Group Vice President Shen Jiangguang stated at the Asian Financial Forum that Hong Kong provides an international development environment for artificial intelligence companies, aiding in business expansion and innovation. With the rapid development of artificial intelligence infrastructure, Hong Kong is expected to play a greater role in fields such as data science, fintech, and intelligent manufacturing, becoming a strategic hub connecting mainland China and international markets. Meanwhile, HENGRUI PHARMA Vice Chairman Dai Hongbin emphasized the company's focus on Hong Kong's position in the international innovation ecosystem and looks forward to deepening cooperation to promote breakthroughs in biomedical technology

GF CSI HK Innovative Drugs Industry ETF(QDII)

JD HEALTH

JD-SW

JD LOGISTICS

JD's Shen Jiangguang: Rapid Development of Artificial Intelligence Infrastructure, Hong Kong Expected to Play a Greater Advantage

Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials

Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials

560600

159992

159615

Morgan Stanley has lowered its revenue forecasts for Hengrui Pharma for 2025 to 2027, reducing them by 2.1%, 3.7%, and 1.8%, respectively, mainly due to a decrease in commercial development revenue from GlaxoSmithKline assets and a decline in contributions from the generic drug business, partially offset by an upward revision in innovative drug sales forecasts. Meanwhile, net profit forecasts have been lowered by 7.4%, 8.9%, and 6.5%. The target price has been raised from 86 yuan to 92 yuan, maintaining an "Overweight" rating

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Penghua SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Research Sector 100 ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

Morgan Stanley lowers Hengrui Pharma's revenue and net profit forecast, target price raised to 92 yuan

Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs

Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs

Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs

Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs

Hengrui Pharmaceuticals Gets Nod to Trial Two Tumor Drugs

Hengrui Pharmaceuticals Gets Nod to Trial Two Tumor Drugs

09992

03986

02259

01055

02628

02359

01211

00981

00763

POP MART(09992) rose 9.07%, with a trading turnover 5.9 Billion HKD, and a year-to-date rose 5.1%. GIGADEVICE(03986) rose 5.52%, with a trading turnover 532.3 Million HKD, and a year-to-date rose 88.9%. HENGRUI PHARMA(01276) fell 4.36%, with a trading turnover 161.0 Million HKD, and a year-to-date rose 3.2%. WUXI APPTEC(02359) fell 4.13%, with a trading turnover 672.1 Million HKD, and a year-to-date rose 15.2%.

- The Hang Seng Index decreased by 0.29%, with a year-to-date increase of 3.3%; the Hang Seng Tech Index dropped by 1.16%, also with a 3% rise this year.  
- Pop Mart (09992) rose by 9.07%, achieving a trading volume of 5.88 billion HKD and a year-to-date increase of 5.1%.  
- In contrast, companies like Innovent Biologics (01276) and WuXi AppTec (02359) saw declines of 4.36% and 4.13% respectively, with year-to-date increases of 3.2% and 15.2%.

Top Gainers & Losers

POP MART

GIGADEVICE

ZIJIN GOLD INTL

CHINA SOUTH AIR

CHINA LIFE

WUXI APPTEC

BYD COMPANY

SMIC

Top 5 HK Stock Gainers/Losers (>100B) (1.20)

Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug

Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug

Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation

Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation

The US imposed a 39% tariff on imported gold bars, sparking a rally in gold stocks, with Lao Feng Xiang rising nearly 4% again. The semiconductor sector was dragged down by SMIC's Q2 net profit plunging 19%, with most stocks falling.

SMIC HK SDR 5to1

LAOPU GOLD

ZIJIN MINING

Zijin Mining

SD GOLD

SD-GOLD

FORTIOR

Asymchem

ZHAOJIN MINING

HORIZONROBOT-W

LINGBAO GOLD

INNOSCIENCE

CE HUADA TECH

BATELAB

ZAI LAB

Zai Lab

TIGERMED

Tigermed

FRONTAGE

CHIFENG GOLD

TONGGUAN GOLD

CHI SILVER GP

HUA HONG SEMI

Hua Hong

Hot Trades in Hong Kong Stocks (8.8)｜Gold Sector Rises Across the Board on Tariff Catalysts, SMIC Leads Decline by 6%

Hong Kong stocks continued their upward trend on July 28, with the cryptocurrency, innovative drug, gaming, and insurance sectors performing well. Hong Kong's &#34;Stablecoin Ordinance&#34; will officially take effect on August 1, marking the countdown to stablecoin issuance; the innovative drug sector was boosted by Hengrui Pharmaceuticals securing a $12 billion order; insurance stocks extended their gains as industry anti-internal competition and interest rate cuts improved profit prospects; gaming stocks benefited from Macau's July gaming revenue exceeding expectations and Thailand's withdrawal of the casino bill.

INNOVENT BIO

3SBIO

CSPC PHARMA

OSL GROUP

CPIC

SUNSHINE INS

SANDS CHINA LTD

Sands China

WYNN MACAU

CR HOLDINGS

China Life

SINO BIOPHARM

MELCO INT'L DEV

GUOTAI JUNAN I

AIA-R

AIA Group

SJM HOLDINGS

Hot Trades in Hong Kong Stocks (7.28)｜Cryptocurrency, Innovative Drugs, Insurance, and Gaming Sectors Shine, Hengrui Pharmaceuticals Soars 15% at Midday

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

WuXi AppTec

WUXI BIO

WuXi Biologics

REMEGEN

RemeGen

DUALITYBIO-B

INNOCARE

InnoCare Pharma

AKESO

JOINN

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

On July 11, the three major stock indices in Hong Kong rose together. In terms of sectors, technology stocks rose collectively, and securities and brokerage stocks mostly increased.

ZA ONLINE

MIXUE GROUP

GUMING

LIANLIAN

PICC P&C

MAO GEPING

BLOKS

PING AN

Ping An Ins HK SDR2to1

Ping An

Ping An Insurance

CITIC SEC

CITIC Securities Co., Ltd.

EB SECURITIES

EBSCN

CHICMAX

XIAOMI-W

Xiaomi HK SDR 2to1

Xiaomi Corporation

CHINA EB LTD

BEONE MEDICINES

The Hang Seng Index is approaching its highest level in nearly 3 years, with Chinese brokerage, insurance, and stablecoin concept stocks remaining hot!

CTHRPHA@EC2605A(24119.HK)

Nomura expects Hengrui Pharma's net profit to grow by 30% this year, lowering the target price to 87.49 yuan and continuing to recommend "buy."

Jiangsu Hengrui Medicine Gets Breakthrough Therapy Designation for Cancer Drug

Hengrui Pharma's HRS-4642 injection has been included in the list of breakthrough therapy designations

Hengrui Pharmaceuticals' Gout Drug Application Accepted by Regulators

Jiangsu Hengrui Pharma Delays Board Re-election, Extends Current Directors’ Terms